Korro Bio, Inc. $KRRO

By Microcap Ledger desk · CIK 0001703647

Facts as of Oct 11, 2026, 08:08 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Cambridge, MA
Fiscal year end: December 31
Shares outstanding: 14,725,646 [10-Q 2026-08-06]
as of 2026-08-05

Sources: [10-K 2026-03-12]

What the company doesAI summary of filing

Korro Bio is a biopharmaceutical company developing RNA editing medicines based on its OPERA platform, which uses oligonucleotide-based approaches to harness the body's natural ADAR enzyme to make precise edits to RNA. The company is in the preclinical and research stage, with its most advanced program, KRRO-121 for hyperammonemia, anticipated to advance toward regulatory filing in the second half of 2026, and is not currently revenue-generating. The company also has programs targeting alpha-1 antitrypsin deficiency, amyotrophic lateral sclerosis, and longevity/liver health, as well as up to two partnered programs with Novo Nordisk that entered a 12-month pause in November 2025. [10-K 2026-03-12]

Segments: KRRO-121 (hyperammonemia program), AATD program (alpha-1 antitrypsin deficiency), ALS program, Longevity and liver health program

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	$0.00	−$38.54M	−$33.07M	$24.91M	[10-Q 2026-08-06]
FY ended Dec 2025	$6.39M	−$117.26M	−$78.56M	$21.82M	[10-K 2026-03-12]
FY ended Dec 2024	$2.27M	−$83.58M	−$60.07M	$55.64M	[10-K 2026-03-12]

Quarterly cash burn: −$16.53M
Cash runway Estimate: ~4.5 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-07	9,368,262	[10-Q 2024-11-12]
2025-03-14	9,388,902	[10-K 2025-03-18]
2025-05-05	9,390,492	[10-Q 2025-05-07]
2025-08-08	9,390,903	[10-Q 2025-08-12]
2025-11-10	9,417,295	[10-Q 2025-11-12]
2026-03-10	14,422,571	[10-K 2026-03-12]
2026-05-04	14,422,571	[10-Q 2026-05-07]
2026-08-05	14,725,646	[10-Q 2026-08-06]

Shelf registration: S-3 filed 2026-03-13; declared effective 2026-03-20 [S-3 2026-03-13]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-09-14	Formela Jean Francois	sell	31,888	$14.12	[4 2026-09-15]
2026-09-14	Formela Jean Francois	sell	6,602	$14.12	[4 2026-09-15]
2026-09-11	Formela Jean Francois	sell	8,450	$13.99	[4 2026-09-15]
2026-09-11	Formela Jean Francois	sell	1,750	$13.99	[4 2026-09-15]
2026-09-11	Dolan Oliver	sell	5	$13.72	[4 2026-09-14]
2026-09-09	Dolan Oliver	sell	6	$13.60	[4 2026-09-10]
2026-09-08	Dolan Oliver	sell	7,347	$13.51	[4 2026-09-10]
2026-08-26	Formela Jean Francois	sell	249	$13.96	[4 2026-08-28]
2026-08-26	Formela Jean Francois	sell	51	$13.96	[4 2026-08-28]
2026-08-19	Formela Jean Francois	sell	23,584	$14.00	[4 2026-08-21]
2026-08-19	Formela Jean Francois	sell	4,884	$14.00	[4 2026-08-21]
2026-08-11	Formela Jean Francois	sell	1,775	$13.96	[4 2026-08-13]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-10-05	8-K	Other events
2026-08-19	8-K	Other events
2026-08-14	13G/A	Beneficial ownership report (5%+ holder)
2026-08-06	10-Q	Quarterly report
2026-08-06	8-K	Material agreement entered; Results of operations; Unregistered sale of equity
2026-08-04	13D/A	Beneficial ownership report (5%+ holder)
2026-07-29	13G	Beneficial ownership report (5%+ holder)
2026-06-11	8-K	Shareholder vote results
2026-05-19	8-K	Other events
2026-05-15	13G/A	Beneficial ownership report (5%+ holder)
2026-05-12	424B3	Prospectus or prospectus supplement
2026-05-07	10-Q	Quarterly report

Facts as of Oct 11, 2026, 08:08 AM UTC. Small caps move fast; check the latest filings.